FOR IMMEDIATE RELEASE

Press Contact:
Cerexa‚ Inc.
Stan Abel
Phone: 510–747–3911
seabel@cerexa.com

Press Contact:
Noonan Russo
Jane Petrino
Phone: 212–845–4274
jane.patrino@eurorscg.com

Cerexa to Present at Rodman & Renshaw Healthcare Conference

ALAMEDA‚ Calif.‚ November 7‚ 2005 –– Cerexa‚ Inc. (www.cerexa.com) today announced that Dennis G. Podlesak‚ Chief Executive Officer‚ will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York‚ NY on Wednesday‚ November 9‚ 2005 at 4:00 p.m. EST at the New York Palace Hotel. Mr. Podlesak will provide a brief corporate overview and discuss the company’s lead product candidate‚ PPI–0903.

About Cerexa

Cerexa‚ Inc.‚ located in Alameda‚ California‚ is an innovation driven‚ biopharmaceutical company committed to developing and commercializing a growing portfolio of novel anti–infective therapies for the treatment of serious and life–threatening infections. Cerexa’s lead compound‚ ceftaroline acetate‚ is a next–generation cephalosporin that is currently being investigated as a potential treatment for cSSSI. Cerexa licensed from Takeda Pharmaceutical Company Limited the exclusive right to develop and commercialize ceftaroline. For additional company information‚ please visit www.cerexa.com.

###